The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2017

Filed:

Aug. 08, 2014
Applicant:

Takeda Pharmaceutical Company Limited, Osaka-shi, Osaka, JP;

Inventors:

Jumpei Aida, Fujisawa, JP;

Yayoi Yoshitomi, Fujisawa, JP;

Yuko Hitomi, Fujisawa, JP;

Naoyoshi Noguchi, Fujisawa, JP;

Yasuhiro Hirata, Fujisawa, JP;

Hideki Furukawa, Fujisawa, JP;

Akito Shibuya, Fujisawa, JP;

Koji Watanabe, Fujisawa, JP;

Yasufumi Miyamoto, Fujisawa, JP;

Tomohiro Okawa, Fujisawa, JP;

Nobuyuki Takakura, Fujisawa, JP;

Seiji Miwatashi, Tokyo, JP;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 211/34 (2006.01); C07D 211/22 (2006.01); C07D 213/30 (2006.01); C07D 401/10 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 413/10 (2006.01); C07D 413/14 (2006.01);
U.S. Cl.
CPC ...
C07D 211/34 (2013.01); C07D 211/22 (2013.01); C07D 213/30 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 413/10 (2013.01); C07D 413/14 (2013.01);
Abstract

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.


Find Patent Forward Citations

Loading…